We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Better Therapeutics Inc | NASDAQ:BTTX | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.0446 | 0.046 | 0.0462 | 0 | 00:00:00 |
Better Therapeutics, Inc.
548 Market Street #49404
San Francisco, California 94104
March 1, 2024
Via EDGAR Transmission
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re: | Better Therapeutics, Inc. |
Registration Statement on Form S-1 (File No. 333-268706)
Ladies and Gentlemen:
Pursuant to Rule 477 promulgated under the Securities Act of 1933, as amended (the Securities Act), Better Therapeutics, Inc. (the Company) hereby respectfully requests that the Securities and Exchange Commission (the Commission) consent to the withdrawal, effective as of the date hereof or at the earliest practicable date hereafter, of its Registration Statement on Form S-1 (File No. 333-268706), together with all exhibits thereto, filed on December 7, 2022, as amended (the Form S-1 Registration Statement).
The Company is seeking withdrawal of the Form S-1 Registration Statement because the Company does not expect to proceed with an offering thereunder.
The Company confirms that the Form S-1 Registration Statement has not been declared effective and confirms that no securities of the Company were sold under the Form S-1 Registration Statement.
The Company requests that, in accordance with Rule 457(p) under the Securities Act, all fees paid to the Commission in connection with the filing of the Form S-1 Registration Statement be credited for future use.
If you have any questions regarding this request, please contact Shoaib Ghias of Goodwin Procter LLP at (415) 733-6150.
Sincerely, |
Better Therapeutics, Inc. |
/s/ Frank Karbe |
Frank Karbe |
Chief Executive Officer |
cc: |
Leslie Miller, Better Therapeutics, Inc. | |
Sam Zucker, Goodwin Procter LLP | ||
Shoaib Ghias, Goodwin Procter LLP |
1 Year Better Therapeutics Chart |
1 Month Better Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions